Stocklytics Platform
Asset logo for symbol CRL
Charles River Laboratories International
CRL59
$197.75arrow_drop_down1.74%-$3.51
S&P500
Asset logo for symbol CRL
CRL59

$197.75

arrow_drop_down1.74%

Performance History

Chart placeholder
Key Stats
Open$198.75
Prev. Close$201.30
EPS8.01
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range194.24
202.96
52 Week Range161.65
275.00
Ratios
EPS8.01

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Charles River Laboratories International (CRL)

Charles River Laboratories International Inc. (CRL) is a leading provider of essential products and services to help pharmaceutical and biotechnology companies accelerate their research and drug development. With a rich history dating back to 1947, the company has established itself as a trusted partner in the scientific community. CRL stock has a long track record of delivering strong financial performance and has consistently outperformed the broader market.
The company's stock price history reflects its solid growth trajectory. Over the past five years, CRL stock has more than doubled in value, demonstrating its ability to generate value for shareholders. The stock has also consistently outperformed its industry peers, highlighting the strong fundamentals and competitive advantage of Charles River Laboratories.
Websitecall_made
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. James C. Foster J.D.
Headquarters
Wilmington
Employees
20000
Exchange
NYSE
add Charles River Laboratories International to watchlist

Keep an eye on Charles River Laboratories International

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Charles River Laboratories International 's (CRL) price per share?

The current price per share for Charles River Laboratories International (CRL) is $197.75. The stock has seen a price change of -$3.51 recently, indicating a -1.74% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Charles River Laboratories International (CRL)?

For Charles River Laboratories International (CRL), the 52-week high is $275, which is 39.06% from the current price. The 52-week low is $161.65, the current price is 22.33% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Charles River Laboratories International (CRL) a growth stock?

Charles River Laboratories International (CRL) has shown an average price growth of -3.4% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Charles River Laboratories International as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Charles River Laboratories International (CRL) stock price performance year to date (YTD)?

As of the latest data, Charles River Laboratories International (CRL) has a year-to-date price change of -15.58%. Over the past month, the stock has experienced a price change of 8.58%. Over the last three months, the change has been -3.35%. Over the past six months, the figure is -7.81%. Looking at a longer horizon, the five-year price change stands at 36.57%.
help

Is Charles River Laboratories International (CRL) a profitable company?

Charles River Laboratories International (CRL) has a net income of $480.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 36.39% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 14.69% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $4.13B, with a revenue growth rate of 3.86%, providing insight into the company's sales performance and growth. The gross profit is $1.5B. Operating income is noted at $617.26M. Furthermore, the EBITDA is $990.36M.
help

What is the market capitalization of Charles River Laboratories International (CRL)?

Charles River Laboratories International (CRL) has a market capitalization of $10.01B. The average daily trading volume is 197.08, indicating the stock's liquidity and investor engagement.

News

Bioprocess Validation Market to Witness 9.10% CAGR by 2031 | SkyQuest Technology
BIOPROCESS VALIDATION
BIOPHARMACEUTICALS
BIOLOGICS
BIOMANUFACTURING
Nov 19, 2024

Bioprocess Validation Market to Witness 9.10% CAGR by 2031 | SkyQuest Technology

Pharmaceutical Sterility Testing Market to Drive Revenue to USD 3.79 Billion by 2032 | CAGR 11.58%
PHARMACEUTICAL STERILITY TESTING
MARKET GROWTH
TECHNOLOGICAL ADVANCEMENTS
BIOPHARMACEUTICALS
REGULATORY COMPLIANCE
Nov 15, 2024

Pharmaceutical Sterility Testing Market to Drive Revenue to USD 3.79 Billion by 2032 | CAGR 11.58%

Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc.
FRAGMENT-BASED DRUG DISCOVERY
PHARMACEUTICAL INDUSTRY
DRUG DEVELOPMENT
Oct 29, 2024

Fragment Based Drug Discovery Market Size Projected to Achieve USD 2.1 Billion by 2031, Expanding at a 11.5% CAGR | Analysis by Transparency Market Research, Inc.

Bio Pharma Buffer Market to Reach $2.4 Billion, Globally, by 2033 at 7.8% CAGR: Allied Market Research
BIO PHARMA BUFFER
BIOPHARMACEUTICALS
DRUG DEVELOPMENT
MANUFACTURING
Oct 6, 2024

Bio Pharma Buffer Market to Reach $2.4 Billion, Globally, by 2033 at 7.8% CAGR: Allied Market Research

Protein Expression Market Industry Trends and Global Forecasts to 2035: Since 2023, Over 6,500 Patents Related to Protein Expression have been Granted
PROTEIN EXPRESSION
PROTEIN THERAPEUTICS
EXPRESSION SYSTEMS
MARKET FORECAST
Sep 27, 2024

Protein Expression Market Industry Trends and Global Forecasts to 2035: Since 2023, Over 6,500 Patents Related to Protein Expression have been Granted

Cell-Based Assays Market Size to Grow at 6.4% CAGR and Surpass USD 40.4 Billion by 2034 Amid Rising Research Applications | According to Transparency Market Research Inc.
CELL-BASED ASSAYS
DRUG DISCOVERY
BASIC RESEARCH
MARKET GROWTH
Sep 11, 2024

Cell-Based Assays Market Size to Grow at 6.4% CAGR and Surpass USD 40.4 Billion by 2034 Amid Rising Research Applications | According to Transparency Market Research Inc.

Take Your Investments to a Whole New Level